Evidence map›Paper›PMID 25701232›Full record

ReviewBiochimica et biophysica acta2015

Cationic antimicrobial peptide resistance mechanisms of streptococcal pathogens.

Christopher N LaRock, Victor Nizet

Abstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 114 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Pentamidine inhibition of streptopain attenuatesbioRxiv : the preprint server for biology · 2025
    Article
  9. Transgenic Maize ofMicroorganisms · 2025
    Article
  10. Review
  11. Article
  12. Science advances · 2024
    Article
  13. International journal of veterinary science and medicine · 2024
    Review
  14. Review
  15. Endopeptidase O promotesVirulence · 2023
    Article
  16. Review
  17. Article
  18. Genome Analysis ofApplied and environmental microbiology · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Christopher N LaRockDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA. Electronic address: clarock@ucsd.edu.
Victor NizetDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA; Skaggs School of Medicine and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA; Rady Children's Hospital, San Diego, CA, USA. Electronic address: vnizet@ucsd.edu.
University of California San Diego · US

Funding

Vaccines and Therapies Against BotulismU54AI057153 · NIAID · UNIVERSITY OF CHICAGO · PI CROSSON, SEAN · 2003 to 2013
$87.6M
Cathelicidins in Skin ImmunityR01AI052453 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI GALLO, RICHARD L, NIZET, VICTOR · 2002 to 2017
$5.3M
Cathelicidin in Skin ImmunityR37AI052453 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Richard L Gallo, Victor Nizet · 2019 to 2026
$4.6M
GAS Switch from Colonizing Bacterium to Invasive PathogenR01AI077780 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR · 2008 to 2019
$3.8M
Mechanisms of the M protein in group A Streptococcus virulenceR01AI096837 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PARTHO, NIZET, VICTOR · 2011 to 2015
$2.7M
Safety and Dose Optimization of High-Dose Anakinra in Kawasaki DiseaseP50HD090259 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CAPPARELLI, EDMUND VINCENT, NIZET, VICTOR · 2019 to 2020
$1.4M
NIAID NIH HHS AI052453NIAID NIH HHS AI077780NIAID NIH HHS R01 AI052453NIAID NIH HHS R01 AI077780NIAID NIH HHS R01 AI096837NIAID NIH HHS R37 AI052453NIAID NIH HHS U54 AI057153NICHD NIH HHS P50 HD090259
6 · The paper itself

Abstract

Cationic antimicrobial peptides (CAMPs) are critical front line contributors to host defense against invasive bacterial infection. These immune factors have direct killing activity toward microbes, but many pathogens are able to resist their effects. Group A Streptococcus, group B Streptococcus and Streptococcus pneumoniae are among the most common pathogens of humans and display a variety of phenotypic adaptations to resist CAMPs. Common themes of CAMP resistance mechanisms among the pathogenic streptococci are repulsion, sequestration, export, and destruction. Each pathogen has a different array of CAMP-resistant mechanisms, with invasive disease potential reflecting the utilization of several mechanisms that may act in synergy. Here we discuss recent progress in identifying the sources of CAMP resistance in the medically important Streptococcus genus. Further study of these mechanisms can contribute to our understanding of streptococcal pathogenesis, and may provide new therapeutic targets for therapy and disease prevention. This article is part of a Special Issue entitled: Bacterial Resistance to Antimicrobial Peptides.

Indexed as

Drug Resistance, BacterialAnimalsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesBacterial ProteinsBiological TransportHost-Pathogen InteractionsHumansImmune EvasionImmunity, InnateMembrane Transport ProteinsMicrobial ViabilityProteolysisSignal TransductionStreptococcal InfectionsStreptococcusAnti-Bacterial AgentsAntimicrobial Cationic PeptidesBacterial ProteinsMembrane Transport ProteinsAntimicrobial peptideCathelicidinDefensinLL-37Streptococcus virulence factors, innate immunity

Identifiers

PMID25701232
PMCPMC4539303
OpenAlexW2109091078

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.